Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
J. Ramos Lizana, E. Cassinello Garcia, L.L. Carrasco-Marina, M. Vázquez López, M. Martín González, A. Muñoz Hoyos.
Remisión de la epilepsia tras el comienzo del tratamiento: estudio prospectivo en la infancia.
Rev Neurol, 33 (2001), pp. 1021-1026
[2.]
M.J. McLean, M. Schmutz, A.W. Wamil, H.R. Olpe, C. Portet, K.F. Feldmann.
Oxcarbazepine: mechanisms of action.
Epilepsia, 35 (1994), pp. 59S
[3.]
A.W. Wamil, C. Portet, P.K. Jensen, M. Schmutz, M.J. McLean.
Oxcarbazepine and its monohydroxy metabolite limit action potential firing by mouse central neurons in cell culture.
Epilepsia, 32 (1991), pp. 605S
[4.]
M. Schmutz, F. Brugger, C. Gentsch, M.J. McLean, H.R. Olpe.
Oxcarbazepine: preclinical anticonvulsant profile and putative mechanisms of action.
Epilepsia, 34 (1993), pp. 4750S
[5.]
P. Lloyd, G. Flesch, W. Dieterle.
Clinical pharmacology and pharmacokinetics of oxcarbazepine.
Epilepsia, 35 (1995), pp. 103S
[6.]
E.S. Tecoma.
Oxcarbazepine.
Epilepsia, 40 (1999), pp. 37S-46S
[7.]
A. Baruzzi, F. Albani, R. Riva.
Oxcarbazepine: pharmacokinetic interactions and their clinical relevance.
Epilepsia, 35 (1994), pp. 149S
[8.]
S.C. Schachter, B. Vázquez, R.S. Fisher, K.D. Laxer, G.D. Montouris, D.T. Combs-Cantrell, et al.
Oxcarbazepine: double-blind, randomized, placebo-control, monotherapy trial for partial seizures.
Neurology, 52 (1999), pp. 732-737
[9.]
R.G. Sachdeo, K. Edwards, H. Hasegawa.
Safety and efficacy of oxcarbazepine 1200 mg/day in patients with recent onset partial epilepsy [abstract].
Neurology, 52 (1999), pp. 391A
[10.]
A. Beydoun, R.C. Sachdeo, W.E. Rosenfeld, G.L. Krauss, N. Sessler, P. Mesenbrink, et al.
Oxcarbazepine monotherapy for partial onset seizures: a multicenter, double-blind, clinical trial.
Neurology, 54 (2000), pp. 2245-2251
[11.]
R.C. Sachdeo, A. Beydoun, S.C. Schachter, B. Vázquez, N. Schaul, P. Mesenbrink, et al.
Oxcarbazepine (Trileptal) as monotherapy in patients with partial seizures.
Neurology, 57 (2001), pp. 864-871
[12.]
K.J. Reinikainen, T. Keränen, T. Halonen, H. Komulainen, P.J. Riekkinen.
Comparison of oxcarbazepine and carbamazepine: a double-blind study.
Epilepsy Res, 1 (1987), pp. 284-289
[13.]
M. Dam, R. Ekberg, Y. Loyning, O. Waltimo, K. Jakobsen.
(The Scandinavian Oxcarbazepine Study Group) A double- blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy.
Epilepsy Res, 3 (1989), pp. 70-76
[14.]
W. Christe, G. Kramer, U. Vigonius, H. Pohlmann, B.J. Steinhoff, M.J. Brodie, et al.
A double-blind controlled trial: oxcarbazepine versus sodium valproate in adults with newly diagnosed epilepsy.
Epilepsy Res, 26 (1997), pp. 451-460
[15.]
P.A. Bill, U. Vigonius, H. Pohlmann, C.A. Guerreiro, S. Kochen, D. Saffer, et al.
A double-blind controlled trial of oxcarbazepine versus phenytoin in adults with previously untreated epilepsy.
Epilepsy Res, 27 (1997), pp. 195-204
[16.]
M.M. Guerreiro, U. Vigonius, H. Pohlmann, M.L. De Manreza, N. Fejerman, S.A. Antoniuk, et al.
A double-blind controlled trial of oxcarbazepine versus phenytoin in children and adolescents with epilepsy.
Epilepsy Res, 27 (1997), pp. 205-213
[17.]
G. Barcs, E.B. Walker, C.E. Elger, A. Scaramelli, H. Stefan, Y. Sturm, et al.
Oxcarbazepine placebo-controlled, doseranging trial in refractory partial epilepsy.
Epilepsia, 41 (2000), pp. 1597-1607
[18.]
T.A. Glauser, M. Nidro, T. Sachdeo, L.A. Pasteris, S. Weinstein, B. Abou-Khalil, et al.
Adjunctive therapy with oxcarbazepine in children with partial seizures.
Neurology, 54 (2000), pp. 2237-2244
[19.]
E. Gaily, M.L. Granström, E. Liukkonen.
Oxcarbazepine in the treatment of epilepsy in children and adolescents with intellectual disability.
J Intel Disab Res, 42 (1998), pp. 415S
Copyright © 2003. Elsevier España, S.L.. Todos los derechos reservados